Previous 10 | Next 10 |
Chembio Diagnostics (NASDAQ: CEMI ) -60% after FDA yanks emergency use authorization of COVID-19 blood test. More news on: Chembio Diagnostics, Inc., BioCardia, Inc., Beasley Broadcast Group, Inc., Stocks on the move, , Read more ...
Citing concerns with accuracy, the FDA has revoked the emergency use authorization of Chembio's (NASDAQ: CEMI ) DPP COVID-19 IgM/IgG System, its SARS-CoV-2 antibody test. More news on: Chembio Diagnostics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Edesa Biotech (NASDAQ: EDSA ) +218% on launch of COVID-19 study in Canada. More news on: Edesa Biotech, Inc., Brickell Biotech, Inc., BioHiTech Global, Inc., Stocks on the move, , Read more ...
Chembio Diagnostics (NASDAQ: CEMI ) has received FDA 510(k) clearance to market the DPP Zika IgM System, for the presumptive detection of Zika virus IgM antibodies in whole blood, serum or plasma. More news on: Chembio Diagnostics, Inc., Healthcare stocks news, Stocks...
HAUPPAUGE, N.Y., June 08, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the DPP Zika IgM Sy...
HAUPPAUGE, N.Y., June 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that Chuck Caso has been appointed Vice President of Sales and Marketing for North America, effective ...
U.S. based Chembio Diagnostics, Inc. (NASDAQ: CEMI ) develops and manufactures point-of-care diagnostic tests that detect infectious diseases. While the company's core products in recent years were related to HIV and other viral diseases, Chembio shifted its focus this year towards the COVID...
Chembio Diagnostics (NASDAQ: CEMI ) has closed a multiyear non-exclusive agreement with Thermo Fisher Scientific (NYSE: TMO ) for the distribution of Chembio's DPP COVID-19 System in the U.S. More news on: Chembio Diagnostics, Inc., Thermo Fisher Scientific Inc., Healthcare stocks news, ...
HAUPPAUGE, N.Y., May 18, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has signed a multi-year, non‑exclusive agreement with Thermo Fisher Scientific’s healt...
HAUPPAUGE, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio”), a leading point-of-care diagnostic company focused on infectious diseases, announced today the closing of its previously announced public offering of 2,619,593 shares o...
News, Short Squeeze, Breakout and More Instantly...
Chembio Diagnostics Inc. Company Name:
CEMI Stock Symbol:
NASDAQ Market:
Chembio Diagnostics Inc. Website:
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of ...
MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 ...
MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 10, 2023 ...